Navigation Links
Vitamin D: More may not be better
Date:5/1/2013

In recent years, healthy people have been bombarded by stories in the media and on health websites warning about the dangers of too-low vitamin D levels, and urging high doses of supplements to protect against everything from hypertension to hardening of the arteries to diabetes.

But new research from Johns Hopkins finds that blood levels of the so-called "sunshine vitamin" higher than the top of the range suggested by the Institute of Medicine confer no additional benefit. This finding, combined with results of a previous study by the same group noting potential harm from higher vitamin D levels in healthy people, has urged investigators to prescribe caution.

"Healthy people have been popping these pills, but they should not continue taking vitamin D supplements unchecked," says study leader Muhammad Amer, M.D., M.H.S., an assistant professor in the Division of General Internal Medicine at the Johns Hopkins University School of Medicine. "At a certain point, more vitamin D no longer confers any survival benefit, so taking these expensive supplements is at best a waste of money."

Amer stresses that there are some groups of people elderly, postmenopausal women, and people with kidney disease who do benefit from higher blood levels of a vitamin vital to bone health. Such groups may need to take supplements.

In an article published online in the American Journal of Medicine, Amer and Rehan Qayyum, M.D., M.H.S., also of Johns Hopkins, describe their review of data from more than 10,000 participants in the National Health and Nutrition Examination Survey (NHANES) from 2001 to 2004. They matched those data with mortality data from the National Death Index through Dec. 2006.

When they looked at deaths from all causes and cardiovascular disease specifically, those with blood levels of 21 nanograms per milliliter of 25-Hydroxyvitamin D at the top of the range that the IOM considers "adequate" and at the low end of "
'/>"/>

Contact: Stephanie Desmon
sdesmon1@jhmi.edu
410-955-8665
Johns Hopkins Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. The right amount of vitamin D for babies
2. Low vitamin D levels a risk factor for pneumonia
3. Researchers pinpoint upper safe limit of vitamin D blood levels
4. Zebrafish study suggests that vitamin B2 (riboflavin) is an antidote to cyanide poisoning
5. Optimal vitamin D dosage for infants uncertain
6. Vitamin E identified as potential weapon against obesity
7. Quit smoking? Vitamin E may give extra boost to heart health
8. Excess vitamin E intake not a health concern
9. Vitamin P as a potential approach for the treatment of damaged motor neurons
10. Vitamin D benefits breathing in tuberculosis patients
11. Living in a sunny climate does not improve vitamin D levels in hip fracture patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... June 15 Robert H. Wurtz, PhD, a pioneer and ... the 2010 Neuroscience Prize of The Peter and Patricia Gruber ... and controls eye movements laid the groundwork for subsequent research ... scientists to a deeper understanding of how the brain is ...
... new study shows that humans and tiny aquatic animals known ... to sex. Barely visible without a microscope, rotifers eat ... But the females of certain rotifer species can do something ... themselves, or they can initiate a process that allows sexual ...
... part of the 20th century have prevented massive amounts ... equivalent of 590 billion metric tons of carbon dioxide ... Stanford Earth scientists. The yield improvements reduced the ... typically involves burning of trees and other plants, which ...
Cached Biology News:Neuroscientist Robert H. Wurtz receives the $500,000 Gruber neuroscience prize 2Neuroscientist Robert H. Wurtz receives the $500,000 Gruber neuroscience prize 3New study documents use of hormone progesterone in simple microscopic aquatic animals 2New study documents use of hormone progesterone in simple microscopic aquatic animals 3New study documents use of hormone progesterone in simple microscopic aquatic animals 4High-yield agriculture slows pace of global warming, say Stanford researchers 2High-yield agriculture slows pace of global warming, say Stanford researchers 3High-yield agriculture slows pace of global warming, say Stanford researchers 4
(Date:5/27/2015)... May 27, 2015 Expanding in a ... manufacturer Avalon Biomed Inc. recently inked a ... Mokuda Dental Co. Ltd. , the largest endodontic distributor ... the international market for Avalon Biomed, which manufactures Grey ... tricalcium silicate-based dental cements that have won renown from ...
(Date:5/27/2015)... SAN FRANCISCO, Calif. , May 27, 2015 ... for the treatment of cancer, today announced the ... financial officer and Cynthia Ladd as ... joining CytomX, Goeltz was chief financial officer of ... served as an independent consultant and legal counsel ...
(Date:5/27/2015)... , May 27, 2015  RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... an update on the status of the Company,s ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... 3,085 and 21 shares of Series A Preferred ...
(Date:5/26/2015)... WORMS, GERMANY (PRWEB) May 26, 2015 ... W. R. Grace & Co. (NYSE: GRA) announces ... received good manufacturing practice (GMP) certification from EXCiPACTâ„¢, ... distributors of pharmaceutical excipients. , All ... brand of pharmaceutical grade excipient silica gels have ...
Breaking Biology Technology:Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
... revolutionary surgical instrument system that is smaller in diameter than a ... implantation of the VerteLoc™ Minimally Invasive Spine Stabilization System and will ... Arizona starting on March 12, 2009. , ... Winston-Salem, ...
... In ClearTrial v2.7, the newest version of ... Portfolio Planning capability which enables clinical development ... into portfolio-level forecasts in minutes. The ... monthly resource demand, and timelines across a ...
... Enobia Pharma, an emerging Canadian biotech company ... disorders, today announced completion of target enrollment in ... a severe form of hypophosphatasia. Enobia is ... the treatment of this rare and often crippling ...
Cached Biology Technology:VGI Announces the Launch of DISMISS Instruments for the VerteLoc™ Minimally Invasive Spine Stabilization System 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 3ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 4Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 2Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 3
... (phospho S207) ( Abpromise for ... Antigen: Synthetic phosphopeptide derived from ... of Serine 207 (V-D-S P -V-A). ... 5608 Swiss ...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Goat polyclonal to ORC2L ( Abpromise for all tested applications). entrezGeneID: 4999 SwissProtID: Q13416...
Biology Products: